|Bid||7.38 x 1200|
|Ask||7.72 x 800|
|Day's range||7.14 - 9.92|
|52-week range||7.00 - 22.22|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.00|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
The big shareholder groups in Biomea Fusion, Inc. ( NASDAQ:BMEA ) have power over the company. Large companies usually...
Especially for companies that are expected to be growing right out of the gate, getting in during the market's initial feeding frenzy sometimes means buying a stock when it's as cheap as it will ever be. In this vein, Recursion Pharmaceuticals (NASDAQ: RXRX) and Biomea Fusion (NASDAQ: BMEA) are a pair of biotechs that had their IPOs last week, and both have unique value for investors that could make them worth a (speculative) buy. Recursion's information technology-heavy approach to drug discovery could make it a rising star on the basis of its already extensive list of development collaborations alone.